LOSARTAN POTASSIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Losartan Potassium, and when can generic versions of Losartan Potassium launch?
Losartan Potassium is a drug marketed by Aiping Pharm Inc, Alembic Pharms Ltd, Apotex, Apotex Corp, Aurobindo Pharma, Chartwell Rx, Granules, Hetero Labs Ltd V, Hikma, Hisun Pharm Hangzhou, Ipca Labs Ltd, Jubilant Cadista, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, MSN, Mylan, Prinston Inc, Strides Pharma, Teva, Torrent Pharms, Unichem, Watson Labs, Zydus Pharms Usa Inc, Sandoz, and Teva Pharms. and is included in forty-one NDAs.
The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOSARTAN POTASSIUM?
- What are the global sales for LOSARTAN POTASSIUM?
- What is Average Wholesale Price for LOSARTAN POTASSIUM?
Summary for LOSARTAN POTASSIUM
US Patents: | 0 |
Applicants: | 26 |
NDAs: | 41 |
Finished Product Suppliers / Packagers: | 45 |
Raw Ingredient (Bulk) Api Vendors: | 139 |
Clinical Trials: | 86 |
Patent Applications: | 3,698 |
Drug Prices: | Drug price information for LOSARTAN POTASSIUM |
Drug Sales Revenues: | Drug sales revenues for LOSARTAN POTASSIUM |
DailyMed Link: | LOSARTAN POTASSIUM at DailyMed |
Recent Clinical Trials for LOSARTAN POTASSIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Gadjah Mada University | Phase 1/Phase 2 |
Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Massachusetts General Hospital | Early Phase 1 |
Pharmacology for LOSARTAN POTASSIUM
Drug Class | Angiotensin 2 Receptor Blocker |
Mechanism of Action | Angiotensin 2 Receptor Antagonists |